- Intellia Therapeutics Stock Drops as Safety Fears Emerge in Drug Trial Barron’s
- Intellia Therapeutics Provides Update on MAGNITUDE Clinical Trials of Nexiguran Ziclumeran (nex-z) Intellia Therapeutics
- For Intellia Therapeutics, CRISPR drug’s safety concern is an existential threat statnews.com
- Intellia tumbles after serious liver toxicity pauses Phase III trials FirstWord Pharma
- Intellia Pauses Crispr Trials After Patient Is Hospitalized Bloomberg.com
